Safety and immunogenicity of two subunit influenza vaccines in healthy children, adults and the elderly: A randomized controlled trial in China

Vaccine

Volumn 26, Issue 35, 2008, Pages 4579-4584

  Zhu, Feng Cai ^a   Zhou, Weizhong ^a   Pan, Hongxing ^a   Lu, Lily ^b   Gerez, Lisya ^c   Nauta, Jos ^c   Giezeman, Katinka ^c   de Bruijn, Iris ^c  

^a JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Solvay(Shanghai) Co Ltd   (China)

^c Solvay Biologicals   (Netherlands)

Author keywords

Children; Influenza; Subunit influenza vaccine; Vaccination

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; MEMBRANE ANTIGEN; SUBUNIT VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; NECK PAIN; NORMAL HUMAN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SEROCONVERSION; SINUSITIS; TONSILLITIS; VACCINATION; VIRUS STRAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINES, SUBUNIT;

EID: 48449103434     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.082     Document Type: Article

References (37)

1. Centers for Disease Control and Prevention. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 56 RR 6 (2007) 1-54
2. Heikkinen T., Booy R., Campins M., et al. Should healthy children be vaccinated? A consensus report of the Summits of Independent European Vaccination Experts. Eur J Pediatr 165 (2006) 223-228
3. Poehling K.A., Edwards K.M., Weinberg G.A., et al. The underrecognized burden of influenza in children. N Engl J Med 355 (2006) 31-40
4. Neuzil K.M., Mellen B.G., Wright P.F., Mitchel E.F., and Griffin M.R. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 342 (2000) 225-231
5. Heikkinen T., Silvennoinen H., Peltola V., et al. Burden of influenza in children in the community. J Infect Dis 190 (2004) 1369-1373
6. Tsolia M.N., Logotheti I., Papadopoulos N.G., et al. Impact of influenza infection in healthy children examined as outpatients and their families. Vaccine 24 (2006) 5970-5976
7. Nichol K.L. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 21 (2003) 1769-1775
8. World Health Organization. Influenza vaccines. Wkly Epidemiol Rec 75 (2000) 281-288
9. Hambridge S.J., Glanz J.M., France E.K., et al. Safety of trivalent inactivated influenza vaccine in children 6-23 months old. JAMA 296 (2006) 1990-1997
10. China Influenza Vaccination Guide. MoH/Disease control/No. 231. MoH, 2005.
11. Palmer D.F., Dowdle W.R., Coleman M.T., and Schild G.C. Advanced laboratory techniques for influenza diagnosis. Part 2. Hemagglutination inhibition test (1975), US Department of Health Education and Welfare, PHS, Atlanta p. 25-62
12. Committee for Medicinal Products for Human Use. Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96. Issued 12 March 1997. www.emea.europa.eu/pdfs/human/bwp/021496en.pdf. Last accessed April 29, 2008.
13. Nauta J. Statistical analysis of influenza vaccine lot consistency studies. J Biopharm Stat 16 (2006) 443-452
14. International Conference on Harmonization (ICH) E9 Expert Working Group. Statistical Principles for Clinical Trials. CPMP/ICH/363/96 1998.
15. Schaad U.B., Bühlmann U., Burger R., et al. Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis. Antimicrob Agents Chemother 44 (2000) 1163-1167
16. Brydak L.B., Rokicka-Milewska R., Machala M., Jackowska T., and Sikorska-Fic B. Immunogenicity of subunit trivalent influenza vaccine in children with acute lymphoblastic leukaemia. Pediatr Infect Dis J 17 (1998) 125-129
17. Brydak L.B., Rokicka-Milewska R., Machala M., and Jackowska T. Studies on the humoral immune response to hemagglutinin of influenza vaccine in children with acute lymphoblastic leukemia after chemotherapy treatment. Int J Pediatr Hematol Oncol 7 (2000) 29-40
18. ®) in high-risk children aged 6 months to 4 years. Br J Clin Pract 51 (1997) 87-90
19. Bueving H.J., Bernsen R.M.D., de Jongste J.C., et al. Influenza vaccination in children with asthma. Randomized double-blind placebo-controlled trial. Am J Respir Crit Care Med 169 (2004) 486-493
20. Beyer W.E.P., Palache A.M., and Osterhaus A.D.M.E. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split virus vaccines. A review and meta-analysis of the literature. Clin Drug Invest 15 (1998) 1-12
21. Ghendon Y.Z., Kaira A.N., and Elshina G.A. The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly. Epidemiol Infect 134 (2006) 71-78
22. Eyubova A., and Nasrullayeva G.M. Combined use of the Influvac vaccine and the immunomodulator IRS-19 in the prophylaxis and treatment of viral respiratory infections [in Russian]. Azerbaijan Metabolism J (2001) 27-30
23. Eyubova A.A., Safaraliyeva E.S., and Efendiyeva N.E. Efficacy of the Influvac vaccine for the prophylaxis of influenza in children with respiratory disease [in Russian]. Azerbaijan Med J 2 (2004) 62-65
24. Dong P., Li Y., Zheng T., et al. Comparative study on the safety and immunogenicity of influenza inactivated subunit vaccine and split vaccine [in Chinese]. Chin J Epidemiol 24 (2003) 570-573
25. Zu R-Q, Fang H-H, F Y-H. A clinical trial of adverse reaction and immunogenicity of domestic lytic influenza virus vaccine. Chin J Biol 2005;18:69-72.
26. Hu Y-H, Fang H-H, G G-H. Evaluation on the safety and immunogenicity of Canada split virus vaccination. Chin J Epidemiol 2005;26:503-6.
27. Zhang X-F, Fang H-H, J Z. Evaluation on the safety and immunogenicity of split influenza virus vaccine. Chin J Vaccines Immun 2005;11:348-51.
28. Hu Y-M, Tan Z-Y, W Y-S. Evaluation of safety and immunogenicity of split influenza vaccine. Chin J Dis Control 2006;10:386-8.
29. Wu J.-D., Fang H.-H., and Tan W.-W. Evaluation on safety and immunogenicity of Inflexal Berna subunit influenza virus vaccine. Chin J Vaccines Immun 12 (2006) 411-414
30. Khan A.S., Polezhaev F., Vasiljeva R., et al. Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren. J Infect Dis 173 (1996) 453-456
31. Halperin S.A., Smith B., Mabrouk T., et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 20 (2002) 1240-1247
32. Esposito S., Marchisio P., Bosis S., et al. Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years. Vaccine 24 (2006) 629-635
33. Ozgur S.K., Beyazova U., Kemaloglu Y.K., et al. Effectiveness of inactivated influenza vaccine for prevention of otitis media in children. Pediatr Infect Dis J 25 (2006) 401-404
34. Salo H., Kilpi T., Sintonen H., Linna M., Peltola V., and Heikkinen T. Cost-effectiveness of influenza vaccination of healthy children. Vaccine 24 (2006) 4934-4941
35. Keren R., Zaoutis T.E., Saddlemire S., Luan X.Q., and Coffin S.E. Direct medical cost of influenza-related hospitalizations in children. Pediatics 118 (2006) 1321-1327
36. European Centre for Disease Prevention and Control. Technical report of the Scientific Panel on Vaccines and Immunisation. Infant and children seasonal immunisation against influenza on a routine basis during inter-pandemic period. January 2007. http://ecdc.europa.eu/documents/pdf/Flu_vacc_18_Jan.pdf. Last accessed April 29, 2008.
37. Palache A.M., Nauta J., de Regt V., and de Bruijn I.A. Twenty years' experience with the safety and immunogenicity of an inactivated subunit influenza vaccine. J Drug Assess 8 (2005) 1-15